埃克替尼治疗30例晚期非小细胞肺癌的近期疗效及安全性分析

The clinical efficacy and tolerability of Icotinib in 30 advanced NSCLC patients

目的:探讨埃克替尼治疗30例NSCLC患者的近期疗效及安全性。方法:对30例患者进行随访,治疗方法为每次125mg,每日3次,口服埃克替尼药物,收集用药后2个月及4个月疗效评价及不良反应。结果:2个月疗效评价PR17例,SD7例,PD6例,客观有效率56.7%,疾病控制率80%;4个月PR15例,SD5例,PD11例,客观有效率51.7%,疾病控制率68.9%;不良反应主要是皮疹及腹泻,仅皮疹有3例Ⅲ～Ⅳ度。结论:埃克替尼治疗晚期NSCLC具有较好的近期疗效及安全性。

Objective： Evaluate the clinical efficacy and tolerability of Icotinib in thirty advanced NSCLC patients.Methods： Thirty NSCLC patients were treated with Icotinib 125mg three times a day until disease progression or unacceptable toxicity.Results： By two months,the objective response rate（ORR）was 56.7% and disease control rate（DCR）was 80%,including partial response（PR） of 17 cases,stable disease（SD） of 7 cases and progressive disease（PD） of 6 cases.By four months,the ORR was 51.7% and DCR was 68.9%,including PR of 15 cases,SD of 5 cases and PD of 11 cases.Adverse reaction is mainly rash and diarrhea.Conclusion： Icotinib have better curative effect and insignificant adverse reaction in the treatment of NSCLC.